Adagrasib

SEP 8, 2026 · PHASE 1 TRIAL

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

ClinicalTrials.gov

Phase 1 dose-escalation study of a novel combination in advanced solid tumors, terminated after enrolling only 6 participants; no results are posted in this registry record.

AUG 14, 2026 · PHASE 3 TRIAL

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcomes are not yet reported.

AUG 11, 2026 · PHASE 1 TRIAL

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

ClinicalTrials.gov

Phase 1 study of a novel drug combination in advanced NSCLC; registry record with no results posted; designed to evaluate safety in a small population.

MAR 25, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Krazati (Labeling)

U.S. Food and Drug Administration

This is an FDA supplemental approval action for a labeling change to adagrasib; it documents an administrative decision, not clinical efficacy or safety data.